Global Top 10 Drug Delivery Technologies Market (2008 – 2015)

The increasing demand for effective delivery of novel biopharmaceuticals is driving the growth of the global top 10 drug delivery technologies market. Further, patent expirations of drugs is also boosting market growth. The global top 10 drug delivery technologies market is expected to grow from $43.8 billion in 2009 to $81.5 billion in 2015, at an estimated CAGR of 11% from 2010 to 2015. The time release technologies market commands the largest share of the overall top 10 drug delivery technologies market owing to immense popularity of once-daily formulations.

Unconventional modes of drug delivery such as pulmonary, nasal and transdermal are gaining a lot of popularity especially in chronic disease conditions such as diabetes, hypertension, CNS and cancer. Nanotechnology advances have led to the development of innovative drug delivery systems.

Scope of the report

This research report categorizes the global market top 10 drug delivery technologies on the basis of their growth, therapeutic areas, patents registered, and industry focus. The report analyzes geography; forecasting revenues and trends in each of the following submarkets:
• Time release technologies
• Targeted delivery
• Aerosol technology
• Encapsulation technology
• Topical formulations
• Injectables
• Trandermal patch
• Implant technology
• Liposomal drug delivery
• PEGlyation technology

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 20 company profiles covering all the sub-segments.

What makes our reports unique?

- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
- We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
- We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
- Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

- Which are the high-growth segments/cash cows and how is the market segmented in terms of the top 10 drug delivery technologies?
- What are market estimates and forecasts; which markets are doing well and which are not?
- Where are the gaps and opportunities; what is driving the market?
- Which are the key playing fields? Which are the winning edge imperatives?
- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We  inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

EXECUTIVE SUMMARY
? OBJECTIVE
? MARKET SCENARIO
? EMERGING TECHNOLOGIES

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY

2 SUMMARY

3 MARKET OVERVIEW
3.1 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE
3.2 STAKEHOLDERS
3.3 CHALLENGES
3.3.1 GOVERNMENT REGULATIONS
3.3.2 PRICING PRESSURE, REIMBURSEMENT, & THIRD-PARTY DEPENDENCE
3.3.3 PATENT LITIGATION
3.4 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS
3.5 PATENT ANALYSIS

4 MARKET DYNAMICS
4.1 DRIVERS
4.1.1 PATENT EXPIRATION OF DRUGS
4.1.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS & BIOPHARMACEUTICALS
4.1.3 REDUCE ATTRITION RATES & SPEED DRUG DISCOVERY/DEVELOPMENT PROCESSES
4.1.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY
4.1.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES
4.2 RESTRAINTS
4.2.1 DRUG FAILURES RAISE CONCERNS OF ROI
4.2.2 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES
4.2.3 U.S. HEALTHCARE REFORMS
4.3 OPPORTUNITIES
4.3.1 HOME-CARE DRUG DELIVERY DEVICES AND SELF-ADMINISTRATION
4.3.2 NICHE THERAPEUTIC AREAS
4.3.3 WELLNESS PRODUCTS

5 TIME RELEASE TECHNOLOGY
5.1 DRIVERS
5.1.1 TIME RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS
5.1.2 ONCE-A-DAY FORMULATIONS
5.1.3 COST EFFECTIVE
5.2 RESTRAINTS
5.2.1 LIMITED NUMBER OF MATERIALS
5.2.2 TECHNICAL BARRIERS
5.3 OPPORTUNITIES
5.3.1 PARTICULATE AND CHRONOPHARMACOKINETIC SYSTEMS
5.3.2 MUCOADHESIVE DRUG DELIVERY
5.4 BIODEGRADABLE POLYMERS
5.5 MULTIPARTICULATE BEAD SYSTEMS
5.6 MATRIX SYSTEMS
5.7 REGULATORY ENVIRONMENT
5.8 TIMED RELEASE VS IMMEDIATE RELEASE FORMULATIONS
5.9 INNOVATIONS IN TIME RELEASE TECHNOLOGIES
5.1 INDUSTRY INSIGHTS
5.11 WINNING IMPERATIVES
5.12 COMPETITIVE DEVELOPMENTS

6 TARGETED DELIVERY
6.1 DRIVERS & RESTRAINTS
6.1.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS
6.1.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR
6.1.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS
6.2 OPPORTUNITY
6.2.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS
6.3 TARGETING LIGANDS
6.4 NON-BIOLOGICAL TARGETING PLATFORMS
6.5 TYPES OF TARGETED THERAPIES & COMPANY FOCUS
6.6 IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS
6.7 INNOVATIONS
6.8 INDUSTRY INSIGHTS
6.9 WINNING IMPERATIVES

7 ENCAPSULATION TECHNOLOGIES
7.1 DRIVERS & RESTRAINTS
7.1.1 ENHANCED BIOAVAILABILITY
7.1.2 EXTENSIVE USAGE IN TASTE MASKING AND FASTER DISSOLVING PILLS
7.1.3 ECONOMICALLY FEASIBLE
7.1.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES
7.2 OPPORTUNITY
7.2.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS
7.3 MICROENCAPSULATION
7.4 NANOENCAPSULATION
7.5 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
7.6 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY
7.7 INDUSTRY INSIGHTS
7.8 WINNING IMPERATIVES
7.9 COMPETITIVE DEVELOPMENTS

8 TOPICAL FORMULATIONS
8.1 DRIVERS & RESTRAINTS
8.1.1 BURN & WOUND TREATMENT
8.1.2 BYPASSING FIRST PASS EFFECT
8.1.3 CONVENIENCE FACTOR
8.1.4 USAGE IN LIMITED THERAPEUTIC AREAS
8.2 OPPORTUNITY
8.2.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS
8.3 GEL TECHNOLOGY
8.4 MICROEMULSIONS
8.5 BIPHASIC SYSTEM
8.6 OTHERS
8.7 INDUSTRY INSIGHTS
8.8 WINNING IMPERATIVES
8.9 COMPETITIVE DEVELOPMENTS

9 AEROSOL TECHNOLOGY
9.1 DRIVERS & RESTRAINTS
9.1.1 INCREASE IN ASTHMA & COPD PATIENTS
9.1.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN
9.1.3 EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY
9.1.4 FAILURE OF EXUBERA
9.2 OPPORTUNITY
9.2.1 APPLICATION IN NON-RESPIRATORY CONDITIONS
9.3 DRY POWDER INHALERS
9.4 METERED DOSE INHALERS
9.5 NEBULIZERS
9.6 EVOLUTION OF AEROSOL TECHNOLOGY
9.7 REGULATORY ENVIRONMENT
9.8 INNOVATIONS IN AEROSOL TECHNOLOGY
9.9 INDUSTRY INSIGHTS
9.1 WINNING IMPERATIVES
9.11 COMPETITIVE DEVELOPMENTS

10 TRANSDERMAL PATCH TECHNOLOGY
10.1 DRIVERS
10.1.1 REDUCED SIDE EFFECTS & BETTER EFFICACY
10.1.2 CONVENIENT AND LESS PAINFUL
10.2 RESTRAINTS
10.2.1 RECALL OF DURAGESIC AND ORTHO EVRA PATCH
10.2.2 LOW SKIN PERMEABILITY OF DRUGS
10.3 OPPORTUNITIES
10.3.1 NEW PRODUCTS
10.4 ADHESIVES
10.5 PHYSICAL ENHANCERS
10.6 CHEMICAL ENHANCERS
10.7 INDUSTRY INSIGHTS
10.8 WINNING IMPERATIVES
10.9 COMPETITIVE DEVELOPMENTS

11 IMPLANT TECHNOLOGY
11.1 DRIVERS & RESTRAINTS
11.1.1 SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT
11.1.2 DOSING ADMINISTRATION NOT REQUIRED
11.1.3 INCONVENIENCE
11.2 OPPORTUNITY
11.2.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS
11.3 MEMS IMPLANTS
11.4 POLYMER WAFERS
11.5 INTRAOCULAR IMPLANTS
11.6 PUNCTAL PLUGS
11.7 INDUSTRY INSIGHTS
11.8 WINNING IMPERATIVES

12 INJECTABLE DRUG DELIVERY TECHNOLOGY
12.1 DRIVERS
12.1.1 FAVORITES FOR DELIVERY OF BIOLOGICAL DRUGS AND GENE THERAPY
12.1.2 GROWTH IN THE PREFILLED SYRINGES AND AUTOINJECTOR MARKET
12.2 RESTRAINTS
12.2.1 INVASIVENESS & FEAR OF INJECTABLES
12.2.2 SELF-ADMINISTRATION REMAINS AN ISSUE
12.3 OPPORTUNITY
12.3.1 MICRONEEDLES & NEEDLELESS SYSTEMS
12.4 EVOLUTION OF INJECTABLES
12.5 INJECTABLE DRUGS IN PIPELINE
12.6 NEEDLESTICK LEGISLATION
12.7 INDUSTRY INSIGHTS
12.8 WINNING IMPERATIVES
12.9 COMPETITIVE DEVELOPMENTS

13 LIPOSOMAL DRUG DELIVERY
13.1 DRIVERS & RESTRAINTS
13.1.1 ENHANCED USAGE IN CANCER
13.1.2 EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS
13.1.3 SIDE EFFECTS
13.2 OPPORTUNITY
13.2.1 NANOSCALE LIPOSOME DRUG DELIVERY
13.3 INDUSTRY INSIGHTS
13.4 WINNING IMPERATIVES
13.5 COMPETITIVE DEVELOPMENTS

14 PEGYLATION TECHNOLOGIES
14.1 DRIVERS & RESTRAINTS
14.1.1 BIOLOGICAL DRUGS
14.1.2 ENHANCED PHARMACOKINETIC PROPERTIES AND REDUCED DOSAGE
14.1.3 EXPENSIVE MANUFACTURING PROCEDURE
14.2 OPPORTUNITY
14.2.1 TECHNOLOGICAL ADVANCES
14.3 INDUSTRY INSIGHTS
14.4 WINNING IMPERATIVES

15 COMPETITIVE LANDSCAPE
15.1 ANALYSIS OF TOP PLAYERS
15.1.1 STRATEGY
15.2 WINNING IMPERATIVES
15.2.1 ALLIANCES
15.2.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY
15.2.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS
15.3 STRATEGIC RECOMMENDATION

16 GEOGRAPHIC ANALYSIS
16.1 NORTH AMERICA
16.2 EUROPE
16.3 ASIA
16.4 ROW

17 COMPANY PROFILES
17.1 ALKERMES, INC
17.1.1 OVERVIEW
17.1.2 PRIMARY BUSINESS
17.1.3 STRATEGY
17.1.4 DEVELOPMENTS
17.2 ALTEA THERAPEUTICS, INC
17.2.1 OVERVIEW
17.2.2 PRIMARY BUSINESS
17.2.3 STRATEGY
17.2.4 DEVELOPMENTS
17.3 AP PHARMA, INC
17.3.1 OVERVIEW
17.3.2 PRIMARY BUSINESS
17.3.3 STRATEGY
17.3.4 DEVELOPMENTS
17.4 APPLIED PHARMA, LTD
17.4.1 OVERVIEW
17.4.2 PRIMARY BUSINESS
17.4.3 STRATEGY
17.4.4 DEVELOPMENTS
17.5 ARADIGM, INC
17.5.1 OVERVIEW
17.5.2 PRIMARY BUSINESS
17.5.3 STRATEGY
17.5.4 DEVELOPMENTS
17.6 BIOJECT, INC
17.6.1 OVERVIEW
17.6.2 PRIMARY BUSINESS
17.6.3 STRATEGY
17.6.4 DEVELOPMENTS
17.7 BIOVAIL, INC
17.7.1 OVERVIEW
17.7.2 PRIMARY BUSINESS
17.7.3 STRATEGY
17.7.4 DEVELOPMENTS
17.8 ELAN CORP, PLC
17.8.1 OVERVIEW
17.8.2 PRIMARY BUSINESS
17.8.3 STRATEGY
17.8.4 DEVELOPMENTS
17.9 ETHYPHARM LTD
17.9.1 OVERVIEW
17.9.2 PRIMARY BUSINESS
17.9.3 STRATEGY
17.9.4 DEVELOPMENTS
17.10 EURAND PHARMACEUTICALS, INC
17.10.1 OVERVIEW
17.10.2 PRIMARY BUSINESS
17.10.3 STRATEGY
17.10.4 DEVELOPMENTS
17.11 JOHNSON & JOHNSON, LTD
17.11.1 OVERVIEW
17.11.2 PRIMARY BUSINESS
17.11.3 STRATEGY
17.11.4 DEVELOPMENTS
17.12 KV PHARMA CORPORATION
17.12.1 OVERVIEW
17.12.2 PRIMARY BUSINESS
17.12.3 STRATEGY
17.12.4 DEVELOPMENTS
17.13 NANOPASS TECHNOLOGIES, LTD
17.13.1 OVERVIEW
17.13.2 PRIMARY BUSINESS
17.13.3 STRATEGY
17.13.4 DEVELOPMENTS
17.14 NEKTAR THERAPEUTICS, LTD
17.14.1 OVERVIEW
17.14.2 PRIMARY BUSINESS
17.14.3 STRATEGY
17.14.4 DEVELOPMENTS
17.15 PENWEST PHARMACEUTICALS, CO.
17.15.1 OVERVIEW
17.15.2 PRIMARY BUSINESS
17.15.3 STRATEGY
17.15.4 DEVELOPMENTS
17.16 QLT, INC
17.16.1 OVERVIEW
17.16.2 PRIMARY BUSINESS
17.16.3 STRATEGY
17.16.4 DEVELOPMENTS
17.17 SKYE PHARMA, PLC
17.17.1 OVERVIEW
17.17.2 PRIMARY BUSINESS
17.17.3 STRATEGY
17.17.4 DEVELOPMENTS
17.18 VECTURA GROUP, PLC
17.18.1 OVERVIEW
17.18.2 PRIMARY BUSINESS
17.18.3 STRATEGY
17.18.4 DEVELOPMENTS
17.19 ENDO PHARMACEUTICALS, INC
17.19.1 OVERVIEW
17.19.2 PRIMARY BUSINESS
17.19.3 STRATEGY
17.19.4 DEVELOPMENTS
17.20 LABOPHARM, INC
17.20.1 OVERVIEW
17.20.2 PRIMARY BUSINESS
17.20.3 STRATEGY
17.20.4 DEVELOPMENTS
17.21 FLAMEL TECHNOLOGIES, INC
17.21.1 OVERVIEW
17.21.2 PRIMARY BUSINESS
17.21.3 STRATEGY
17.21.4 DEVELOPMENTS
17.22 DURECT, CORP
17.22.1 OVERVIEW
17.22.2 PRIMARY BUSINESS
17.22.3 STRATEGY
17.22.4 DEVELOPMENTS
17.23 3M
17.23.1 OVERVIEW
17.23.2 PRIMARY BUSINESS
17.23.3 STRATEGY
17.23.4 DEVELOPMENTS

APPENDIX
? U.S. PATENTS
? EUROPE PATENTS
? JAPAN PATENTS

LIST OF TABLES

1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS 2008 – 2015 ($MILLION)
2 DRUGS EXPECTED TO LOSE PATENT RIGHTS (2010 – 2012)
3 GLOBAL TIME RELEASE TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
4 GLOBAL TIME RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
5 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
6 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
7 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
8 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
9 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
10 GLOBAL TARGETING LIGANDS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
11 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
12 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
13 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
14 GLOBAL MICROENCAPSULATION MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
15 GLOBAL NANOENCAPSULATION MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
16 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
17 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY 2008 – 2015
18 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
19 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
20 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
21 GLOBAL AEROSOL TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
22 GLOBAL AEROSOL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
23 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
24 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
25 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
26 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY PRODUCTS 2008 – 2015 ($MILLION)
27 GLOBAL TRANSDERMAL PATCH TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
28 GLOBAL ADHESIVES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
29 GLOBAL PHYSICAL ENHANCERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
30 GLOBAL CHEMICAL ENHANCERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
31 GLOBAL IMPLANT TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015
32 GLOBAL IMPLANT TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
33 GLOBAL MEMS IMPLANT MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
34 GLOBAL POLYMER WAFERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
35 GLOBAL INTRAOCULAR IMPLANTS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
36 GLOBAL PUNCTAL PLUGS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
37 GLOBAL INJECTABLES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
38 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
39 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
40 ELAN’S PIPELINE DRUGS
41 BIOVAIL’S PIPELINE DRUGS
42 ALKERMES’S PIPELINE DRUGS
43 NEKTAR’S PIPELINE DRUGS
44 SKYE PHARMA’S PIPELINE DRUGS
45 TOP COMPANIES & THEIR STRATEGIES

LIST OF FIGURES

1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES
2 TOP 10 DRUG DELIVERY TECHNOLOGIES – MARKET SHARE
3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY
4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN A DRUG LIFE CYCLE
5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS
6 DRUG DELIVERY MARKET STAKEHOLDERS
7 IMPACT OF MARKET DRIVERS AND RESTRAINTS
8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES
9 PATENT ANALYSIS BY GEOGRAPHY
10 PATENT ANALYSIS BY SEGMENT (2004 – 2009)
11 PATENT ANALYSIS BY ASSIGNEE (2004 – 2009)
12 REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS
13 EVOLUTION OF TIME RELEASE TECHNOLOGIES
14 TIME RELEASE VS IMMEDIATE RELEASE
15 TARGETED THERAPY TYPES
16 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
17 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY
18 EVOLUTION OF AEROSOL TECHNOLOGY
19 EVOLUTION OF INJECTABLES
20 COMPETITIVE DEVELOPMENTS (2007 – JUNE 2010)
21 COMPETITIVE DEVELOPMENTS BY SEGMENT (2007 – JUNE 2010)
22 REVENUE ANALYSIS (2008 – 2009)
23 R&D EXPENDITURE (2009)
24 GLOBAL TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – NORTH AMERICA
26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – EUROPE
27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ASIA
28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ROW